Shopping Cart
- Remove All
- Your shopping cart is currently empty
EGFR Kinase Inhibitor 4 (Compound 4) acts as a bivalent ATP-allosteric inhibitor targeting EGFR, with a potent inhibitory effect (IC 50: 1.8 nM) on mutant EGFR (LRTMCS). It is primarily utilized in the study of non-small cell lung cancer (NSCLC) [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | 10-14 weeks | |
50 mg | Inquiry | 10-14 weeks |
Description | EGFR Kinase Inhibitor 4 (Compound 4) acts as a bivalent ATP-allosteric inhibitor targeting EGFR, with a potent inhibitory effect (IC 50: 1.8 nM) on mutant EGFR (LRTMCS). It is primarily utilized in the study of non-small cell lung cancer (NSCLC) [1]. |
In vitro | EGFR kinase inhibitor 4 (0-10 μM, 6 hours) reduces LRTM phosphorylation (pY1068) and downstream pERK and pAKT in human NSCLC cell lines (H1975, H3255, HCC827 cells) [1]. |
Molecular Weight | 690.75 |
Formula | C40H34N8O4 |
Cas No. | 2922402-05-7 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.